ProSupp for Menarini 8-K
|Filed Pursuant to Rule 424(b)(3)|
|Registration No. 333-261599|
PROSPECTUS SUPPLEMENT NO. 3
(to prospectus dated April 12, 2022)
Context Therapeutics Inc.
This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated April 12, 2022 (the “Prospectus”), related to the disposition, from time to time, by the selling stockholders identified in the Prospectus under the caption “Selling Stockholders” of up to 10,000,000 shares of our common stock, with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “SEC”) on August 02, 2022 (the “Current Report”). Accordingly, we have attached the Current Report to this prospectus supplement
This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on this prospectus supplement.
Our common stock is traded on the Nasdaq Capital Market under the symbol “CNTX.” On August 01, 2022, the last reported closing sale price of our common stock on the Nasdaq Capital Market was $1.89 per share.
We are an “emerging growth company” under the federal securities laws and have elected to comply with certain reduced public company reporting requirements.
Investing in our common stock involves a high degree of risk. See “Risk Factors” beginning on page 11 of the Prospectus to read about factors you should consider before buying shares of our common stock.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this prospectus is August 02, 2022
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 1, 2022
Context Therapeutics Inc.
(Exact name of registrant as specified in its charter)
|(State of other jurisdiction of incorporation)||(Commission File Number)||(I.R.S. Employer Identification No.)|
2001 Market Street, Suite 3915, Unit#15
Philadelphia, Pennsylvania 19103
(Address of principal executive offices including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class
|Trading||Name of exchange|
|Symbol||on which registered|
|Common Stock||CNTX||The Nasdaq Stock Market|
$0.001 par value per share
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement
On August 1, 2022, Context Therapeutics Inc. (the "Company"), entered into a Clinical Trial Collaboration and Supply Agreement (the "Agreement") with Berlin-Chemie AG - Menarini Group - ("Menarini"). Pursuant to the Agreement, Menarini will provide, at no cost to the Company, elacestrant, its nonsteroidal combined selective estrogen receptor modulator and selective estrogen receptor degrader therapy, for use in combination with the Company's investigational drug, onapristone extended-release (“ONA-XR”), in a planned Phase 1/2 clinical trial (the "Study"). Under the Agreement, the Company will sponsor, fund and conduct the Study. Under the Agreement, Menarini has agreed to manufacture and supply elacestrant at Menarini's cost and for no charge to the Company for use in the Study and to provide cfNA analysis of the anonymized blood samples of all Study patients. The Company will own any data and sample testing results produced in the Study. The Company and Menarini will jointly own any rights to inventions relating to the combined use of elacestrant and ONA-XR, while Menarini will own certain inventions solely related to elacestrant and the Company will own certain inventions solely related to ONA-XR. Additionally, should the Study be successful such that the Company or Menarini desires to pursue a Phase 3 study, the other party would be obligated to use commercially reasonable efforts to provide a reasonable supply of such study drug for a Phase 3 study at a reasonable cost. The Company and Menarini will form a joint development committee responsible for coordinating all activities between the parties under the Agreement. Additionally, should the Company receive a bona-fide third-party offer to sell, divest or license ONA-XR, the Company shall, subject to certain exceptions, inform Menarini of the receipt of an offer and, if Menarini timely provides proposed terms for such a transaction in writing, the Company shall consider such terms in good faith.
Until the earlier of (i) Study completion, (ii) the termination of the Study or the Agreement, (iii) the FDA providing a complete response letter (“CRL”) to the application for approval for elacestrant that does not ultimately lead to approval of elacestrant within six (6) months of such initial CRL, or (iv) Menarini’s breach of the terms of the Agreement, Context will not conduct a clinical trial in humans with an orally administered selective estrogen receptor degrader, other than elacestrant, in patients with advanced or metastatic estrogen receptor-positive, progesterone receptor-positive, HER2-negative breast cancer. The Agreement may be terminated by either party (i) in the event of an uncured material breach by the other party, (ii) for safety reasons, (iii) should any regulatory authority take certain actions that suspend or terminate the Study or the other party's ability to provide its Study drug, or (iv) should either party reasonably believe that the Study data shows evidence of lack of efficacy and/or futility that is agreed to by the parties or confirmed by a third-party expert. Further, the Agreement may be terminated by the Company should the Study budget exceed or be anticipated to exceed the initial budget with the primary contract research organization engaged by Context to perform the Study and the Company reasonably determines not to cover the additional costs and expenses. Upon termination other than due to Menarini's material breach, the Company shall return or destroy all unused elacestrant. The agreement contains representations, warranties, undertakings and indemnities customary for a transaction of this nature.
The foregoing is only a summary description of the terms of the Agreement, does not purpose to be complete and is qualified in its entirety by reference to the Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2022.
Item 7.01. Regulation FD Disclosure.
On August 2, 2022, the Company issued a press release announcing its execution of the Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Additionally, on August 02, 2022, the Company updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference.
The information in this Item 7.01, and Exhibits 99.1 and 99.2 attached hereto, are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Item 9.01. Exhibits.
|Exhibit No. ||Description|
|99.1||Press Release issued by Context Therapeutics Inc., dated August 2, 2022.|
|99.2||Context Therapeutics Inc. Corporate Presentation - August 2022.|
|104||Cover Page Interactive Data File (embedded within the inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: August 2, 2022||Context Therapeutics Inc.|
By: /s/ Martin A. Lehr
| Name: Martin A. Lehr|
| Title: Chief Executive Officer|
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
Preclinical data support the potential of ONA-XR plus estrogen receptor degraders in endocrine resistant disease models
Context to initiate Phase 1b/2 clinical trial in Q4 2022
PHILADELPHIA, PA and FLORENCE, Italy— August 02, 2022—Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, and The Menarini Group (“Menarini”) today announced a clinical trial collaboration and supply agreement for Menarini’s oral selective estrogen receptor degrader (SERD), elacestrant.
This agreement will support the upcoming Phase 1b/2 ELONA clinical proof-of-concept trial evaluating onapristone extended release (ONA-XR), an oral progesterone receptor (PR) antagonist, in combination with elacestrant in estrogen receptor positive (ER+), PR+ HER2- metastatic breast cancer (mBC) patients who have previously been treated with a CDK4/6 inhibitor. Context will sponsor the clinical trial and Menarini will supply elacestrant at no cost.
According to the American Cancer Society, breast cancer is the second most common cancer among women occurring in 1 in 8 women (13%) over the course of a woman’s lifetime, with ~280,000 new cases of invasive breast cancer and 51,400 cases of non-invasive breast cancer expected in 2022. Elacestrant is the first oral SERD to demonstrate a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard-of-care (SOC) endocrine therapy in a Phase 3 trial in patients with ER+, HER2- mBC, with 30% reduction in the risk of progression or death in all patients. Data also showed that 22% of patients were alive and progression-free at 12 months after elacestrant treatment initiation vs. 9% with SOC in the overall population. Therefore, elacestrant may become the new backbone endocrine therapy for ER+, HER2- mBC.
Preliminary data from preclinical studies suggest that a dual ER and PR blockade may be associated with enhanced tumor control. The ELONA clinical trial will be evaluating this important hypothesis.
“We are grateful to Menarini for their collaboration as we explore the therapeutic potential of adding ONA-XR, our oral PR antagonist, to elacestrant,” said Tarek Sahmoud, MBBCh, Ph.D., Context’s Chief Medical Officer. “We hope that this combination will further improve the clinical outcome in patients with ER+, PR+, HER2- mBC.”
“ONA-XR’s ability to restore hormone sensitivity and its tolerability profile positions it well for combination with elacestrant,” said Nassir Habboubi, M.D., Menarini’s Global Head of R&D.
Context anticipates initiating the Phase 1b/2 clinical trial in the fourth quarter of 2022. The two companies will form a joint committee to review results.
About Menarini Group
The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of over $4 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for oncology, cardiology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini's products are available in 140 countries worldwide. For further information, please visit www.menarini.com.
ONA-XR (onapristone extended release) is a potent and specific antagonist of the progesterone receptor (PR) that is orally administered. Currently, there are no approved therapies that selectively target PR+ cancers. Preliminary preclinical and clinical data suggest that ONA-XR has anticancer activity by inhibiting progesterone receptor binding to chromatin, downregulating cancer stem cell mobilization and blocking immune evasion. ONA-XR is currently being evaluated in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in PR+ breast, ovarian and endometrial cancers. ONA-XR is an investigational drug that has not been approved for marketing by any regulatory authority.
About Context Therapeutics®
Context Therapeutics Inc. (Nasdaq: CNTX), is a women’s oncology company developing small molecule and immunotherapy treatments to transform care for breast and gynecological cancers. The Company’s robust clinical program for lead candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancer. ONA-XR is a novel, first-in-class small molecule under development as a potent and specific antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women’s cancers. Context is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.
This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, included in this press release regarding strategy, future operations, prospects, plans and objectives of management, including words such as "may," "will," "expect," "anticipate," "plan," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are forward-looking statements. These include, without limitation, statements regarding (i) the timing to initiate, enroll, and obtain initial data for our clinical trials, (ii) the results of our clinical trials, (iii) the potential benefits of the product candidates, (iv) the likelihood data will support future development, and (v) the likelihood of obtaining regulatory approval of the product candidates. Forward-looking statements in this release involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements, and we, therefore cannot assure you that our plans, intentions, expectations, or strategies will be attained or achieved. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in our filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. Except as otherwise required by law, we disclaim any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
|Context Therapeutics||Menarini Group|
Investor Relations Contact:
Valeria Speroni Cardi
Corporate Presentation August 2022 BRINGING CHANGE FOR FEMALE CANCERS
Forward Looking Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “plan”, “predict”, “expect,” “estimate,” “anticipate,” “intend,” “goal,” “strategy,” “believe,” “could”, “would”, “potential”, “project”, “continue” and similar expressions and variations thereof. Forward-looking statements may include statements regarding the Company’s business strategy, cash flows and funding status, potential growth opportunities, clinical development activities, the timing and results of preclinical research, clinical trials and potential regulatory approval and commercialization of product candidates. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements. 2 Context Therapeutics Inc. - August 2022 These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in documents the Company has filed with the SEC. These forward-looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof. Certain information contained in this presentation may be derived from information provided by industry sources. The Company believes such information is accurate and that the sources from which it has been obtained are reliable. However, the Company cannot guarantee the accuracy of, and has not independently verified, such information. Trademarks: The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.
Company Highlights Context Therapeutics Inc. - August 20223 Executive Summary Focus on Women’s Oncology → Unmet clinical need in breast, ovarian, and endometrial cancers Financial Strength → Expected cash runway into Q4 2023 ONA-XR oral PR antagonist → Progesterone receptor (PR) oncogenic signaling is associated with breast, ovarian, and endometrial cancer1 → ONA-XR is a proprietary, oral, extended-release form of onapristone, a potent PR antagonist → ONA-XR is being evaluated in one Phase 1b/2 and three Phase 2 clinical trials → Announced Phase 1b/2 clinical trial with Menarini Group to evaluate elacestrant (oral SERD) plus ONA-XR CLDN6 x CD3 bispecific antibody → Claudin 6 (CLDN6) is uniquely expressed in gynecologic, testicular, lung, and gastric cancers → Developing a highly selective CLDN6 x CD3 bispecific antibody → On track to announce Development Candidate in Q4 2022 (1) Chiebowski, JAMA, 2010; Daniel, Oncogene, 2015 :
Pipeline Executive Summary (1) Tyligand Biosciences Ltd licensed rights to ONA-XR in China, HK, Macau Cancer Clinical Indication Research Phase 1 Phase 2 Phase 3 Upcoming Milestones FDA Fast Track ONA-XR (PR antagonist)1 Breast Cancer 1L ER+,PR+,HER2- ctDNAhigh • Phase 1b data Mid 2023 2L/3L ER+,PR+,HER2- Combination w/ elacestrant • Initiate Q4 2022 2L/3L ER+,PR+,HER2- Combination w/ fulvestrant • Preliminary data Q4 2022 Ovarian Cancer Recurrent PR+ Granulosa Cell • Preliminary data Q4 2022 Endometrial Cancer Recurrent PR+ Endometrioid • Preliminary data Q4 2022 CLDN6xCD3 bispecific antibody Ovarian & Endometrial Cancer • Candidate selection Q4 2022 Phase 1b/2 Trial Phase 1b/2 Trial Phase 2 Trial Phase 2 Trial Phase 2 Trial Context Therapeutics Inc. - August 20224
Progress Since IPO and Follow-on Use of Proceeds • ONA-XR ̶ Q3 2022: clinical trial collaboration with Menarini Group to evaluate elacestrant, an oral Selective Estrogen Receptor Degrader (SERD), plus ONA-XR ̶ Q2 2022: three presentations at AACR highlighting potential of ONA-XR beyond anti-estrogen combination therapy ̶ Q4 2021: window of opportunity trial data identifies markers of response and endocrine sensitivity • CLDN6xCD3 ̶ Q2 2022: two presentations at AACR highlighting bispecific selectivity and T cell-mediated cytotoxicity Context Therapeutics Inc. - August 20225 Recent Announcements • ONA-XR ̶ Initiate Phase 1b/2 combination trial with elacestrant ̶ Prelim. data from Phase 2 trial in mBCa (post-CDK) ̶ Prelim. data from Phase 2 trial in endometrial cancer ̶ Prelim. data from Phase 2 trial in ovarian cancer • CLDN6xCD3 ̶ Nominate development candidate Upcoming 2022 Milestones
ONA-XR Progesterone Receptor Antagonist 6 Context Therapeutics Inc. - August 2022
Onapristone Extended Release (ONA-XR) Context Therapeutics Inc. - August 20227 ONA-XR Mechanism of Action → Onapristone is a progesterone receptor (PR) antagonist that suppresses PR oncogenic signaling → PR oncogenic signaling is associated with breast, ovarian, and endometrial cancer → Onapristone is the only known clinical-stage full PR antagonist Market Opportunity → Breast, ovarian, and endometrial cancers are large and growing markets → Up to 70% of these cancer patients have progesterone receptor positive disease Dosing and Administration → ONA-XR is an extended-release (XR) tablet form of onapristone (ONA) → 50 mg administered orally twice per day Ongoing and Planned Clinical Trials → Drive enrollment in four ongoing clinical trials → Initiate Phase 1b/2 combination clinical trial to evaluate elacestrant (oral SERD) plus ONA-XR Intellectual Property → IP protection through at least 2034
Clinical Development Strategy Blocking cancer growth by combining antiestrogen and antiprogestin therapies Context Therapeutics Inc. - August 20228 ONA-XR Cell Survival Stemness Immune Evasion Proliferation Estrogen Progesterone Cancer Driver Stimulus Cancer Growth and MetastasisOutcome Antiestrogens aromatase inhibitors, SERM, SERCA, injectable SERD, oral SERD Antiprogestin ONA-XR
ONA-XR Evaluation in Breast Cancer Clinical Trials 9 Context Therapeutics Inc. - August 2022 Breast Cancer Treatment Line Context Trial Design Clinical Collaborator Treatment Trial Status PR+ Patients (US)1 Medical Need Adjuvant (after primary disease treatment) Window of Opportunity ONA-XR Completed; Data presented at SABCS ‘21 >>250,000 Enhance antiestrogen potency First-Line Metastatic 1L ER+,PR+,HER2- (ctDNAhigh) ONA-XR + Palbociclib + Letrozole Enrolling patients ~56k Treat patients who are at high risk of early progression Second / Third Line Metastatic 2L/3L ER+,PR+,HER2- (post-CDK4/6i) ONA-XR + Elacestrant Q4 initiation ~35k Improve response rate and progression free survival Second / Third Line Metastatic 2L/3L ER+,PR+,HER2- (post-CDK4/6i) ONA-XR + Fulvestrant Enrolling patients ~35k Improve response rate and progression free survival ONA-XR (1) Secondary epidemiologic estimates, 2020 estimates Developing ONA-XR as an Add-on to Antiestrogen Therapy Across Treatment Lines
ONA-XR Evaluation in Gynecologic Clinical Trials 10 Context Therapeutics Inc. - August 2022 Cancer Context Trial Clinical Collaborator Trial Status PR+ Patients (US)1 Standard of Care (SOC) Medical Need Recurrent Endometrial Combination with Anastrozole in PR+ patients Enrolling Patients ~25k Lenvima + Keytruda Limited treatment options after recurrence Recurrent Granulosa Cell Tumor of Ovary Combination with Anastrozole in PR+ patients Monotherapy Phase Complete; Combination Study Enrolling Patients ~5k Physician’s Choice No FDA approved products in recurrent setting ONA-XR Developing ONA-XR as an Add-on to Antiestrogen Therapy Across Gynecologic Cancers (1) Secondary epidemiologic estimates, 2020 estimates
Elacestrant + ONA-XR Combination Clinical Trial Clinical Trial Collaboration with Menarini Group 11 Context Therapeutics Inc. - August 2022
Rationale for Clinical Trial Collaboration • Elacestrant is the first oral SERD to show positive Ph 3 top line results1 • Submitted NDA in June 2022 • Potential to enhance elacestrant clinical activity in metastatic breast cancer • Establish clinical proof of concept for ONA-XR combination therapy with oral SERD class • ONA-XR is the most complete PR antagonist in clinical development2 • ONA-XR tolerability profile makes it a potentially ideal combination agent3 • Desire to clinically validate combination of ONA-XR with new oral SERDs Menarini Clinical Trial Collaboration Context Therapeutics Inc. - August 202212 (1) “Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021.” Menarini Group, 8 Dec. 2021. Press release (2) Afhuppe, J. Steroid Biochem. Mol. Biol. 2009, 105; Afhuppe, J. Steroid Biochem. Mol. Biol. 2010, 45 (3) Lewis, J. Drug Safety 2020 Clinical Trial Collaboration and Supply Agreement • Phase 1b/2 study of ELacestrant in combination with ONApristone in patients with advanced or metastatic ER+,PR+,HER2- breast cancer (ELONA trial) • Context will sponsor the clinical trial and Menarini Group will supply elacestrant at no cost • Context and Menarini will form a Joint Development Committee to review the clinical trial results Elacestrant + ONA-XR
Elacestrant: Potential to be 1st FDA Approved Oral SERD Strong efficacy/safety data across clinical trials Menarini Clinical Trial Collaboration Context Therapeutics Inc. - August 202213 (1) Patel et al., Breast Cancer Research, 2019 (2) Jager et al., Breast Cancer Research, 2020 (3) Bardia, SABCS, 2021 Elacestrant Control PFS 2.79 months 1.19 months HR=0.697; P = 0.0018 PFS ESR1 mut 3.78 months 1.87 months HR=0.546; P=0.0005 TEAE leading to discontinuation 6.3% 4.4% • Trial met both primary endpoints (PFS, PFS ESR1) • First oral SERD to demonstrate higher efficacy than fulvestrant in a pivotal trial • Well tolerated • Can become standard of care in CDK4/6 inhibitor-resistant population • Selective for estrogen receptor • Target engagement retained in ESR1 mutant • Highly potent and selective oral SERD • Active in models of treatment resistance Selective ER Degrader1 (SERD) Positive PD Response2 Ph 3 (EMERALD) Results3
Elacestrant + ONA-XR: Potential to Improve the Treatment of Breast Cancer • Elacestrant is first oral SERD to show positive top line results in a Phase 3 clinical trial1,2 • If approved, elacestrant has the potential to become the antiestrogen standard of care • When used in combination, ONA-XR may enhance elacestrant clinical activity both in ESR1 mutant and general population Menarini Clinical Trial Collaboration Context Therapeutics Inc. - August 202214 ER+,PR+,HER2- Breast Cancer Treatment Landscape in United States3 Add-on Therapies mTOR inhibitors PI3K inhibitors CDK4/6 inhibitors Antiestrogen Backbone Elacestrant (oral SERD) Elacestrant plus ONA-XR Dev Plan Future (1) Bardia et al, Results of EMERALD phase 3 trial. 2021 SABCS. Abstract GS2-02. Presented December 8, 2021 (2) “Positive EMERALD Trial Results for Elacestrant Presented at San Antonio Breast Cancer Symposium 2021.” Menarini Group, 8 Dec. 2021. Press release. (3) Source: secondary epidemiologic estimates, 2020 estimates Metastatic 2L/3L (~35K) Metastatic 1L (~56K) Adjuvant (>250K) Market Opportunity Near-term ELONA Trial Expansion
Phase 1b/2 (ELONA Trial) – Designed to Evaluate Combination Efficacy and Tolerability • Indication: ER+,PR+,HER2- advanced or metastatic breast cancer • Study: Phase 1b (n=12-28) / Phase 2 (n=45) • Primary Endpoint: overall response rate (ORR) • Secondary Endpoint: progression free survival (PFS), clinical benefit rate (CBR) • Sites: US only, 16-19 sites Menarini Clinical Trial Collaboration Context Therapeutics Inc. - August 202215 Patient Population • Prior therapy with CDK4/6 inhibitor required • No prior chemotherapy in metastatic setting permitted • ≥ 50% of patients will have ESR1 mutation Phase 1b • Dose escalation • 12-28 patients • 4 cohorts Phase 2 • ~45 patients
Claudin 6 Program 16 Context Therapeutics Inc. - August 2022
Claudin 6 (CLDN6) is an Exciting, Emerging Oncology Target Context Therapeutics Inc. - August 202217 CLDN6 x CD3 Bispecific Program Claudins are major components of tight junctions that maintain cell polarity and intercellular adhesion. CLDN6 is a tumor-specific protein in adults that is present in gynecologic cancers, as well as lung, gastric, and testicular cancer. A competing CLDN6-targeting approach, BNT211, achieved a 43% ORR in an early Ph 1 study. Lipase activity was a noted side effect.1 High CLDN6 selectivity is required to avoid potential off target toxicities associated with CLDN3 (liver), CLDN4 (pancreas), and CLDN9 (ear, stomach). CLDN6 is Highly Expressed in Select Solid Tumors2 1 Haanen JB, Mackensen A, Koenecke C, et al. CT002 - BNT211: A Phase I trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6-positive advanced solid tumors. Presented at: American Association for Cancer Research Annual Meeting; April 8-13, 2022; New Orleans, LA. Abstract CT002. 2 Cancer RNAseq data from The Cancer Genome Atlas (TCGA). Normal tissue RNAseq data from the Genotype-Tissue Expression (GTEx)project Ovarian Lung Endometrial Gastric 0 200 400 600 800 Cancerous Healthy
Claudin 18.2 versus Claudin 6 A more advanced Claudin-targeting approach, Claudin 18.2, provides a relevant comparison for Claudin 6 Claudin 18.2 Claudin 6 Most advanced program Phase 3 Phase 1 Competition (clinical) 20+ programs 4 programs Targeting approaches ADC, bispecific, CAR-T, mAb ADC, bispecific, CAR-T Protein expression in normal adult tissue Gastric (differentiated) Not expressed Biomarker prevalence in solid tumors1,2 Gastric (70%) Pancreatic (16%) Testicular (>95%) Ovarian (55%) Endometrial (31%) Lung (16%) Gastric (13%) Bladder (2%) Breast (2%) CLDN6 x CD3 Bispecific Program Context Therapeutics Inc. - August 202218 1) Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021. 2) Reinhard K, Rengstl B, Oehm P, et al . An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors. Science. 2020 Jan 24;367(6476):446-453.
CLDN6xCD3 Bispecific Antibody Program Context Therapeutics Inc. - August 202219 CLDN6 x CD3 Bispecific Program Well characterized anti-CD3gd partner arms Highly specific CLDN6 MAbs generated by Integral Molecular Highly diverse molecular propert ies: SizeAffinity Funct ionSpecif icity 54 Bispecif ic candidates Stoichiometry Geometry α-CLDN6 α-CD3 We have developed a library of CLDN6xCD3 bispecifics • Explored a range of bispecific frameworks, CLDN6 sequences, and CD3 sequences • Comparator bispecifics generated for benchmarking Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022
Our Antibodies Display High Selectivity for CLDN6 CLDN6 x CD3 Bispecific Program Context Therapeutics Inc. - August 202220 Benchmark = IMAB027 Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022 IM171 -10 -9 -8 -7 -6 0 50,000 100,000 150,000 Log [MAb], M M e a n F lu o re s c e n c e IM302 -10 -9 -8 -7 -6 0 50,000 100,000 150,000 Log [MAb], M M e a n F lu o re s c e n c e Benchmark -10 -9 -8 -7 -6 0 50,000 100,000 150,000 hCLDN6 hCLDN9 hCLDN3 hCLDN4 Log [MAb], M M e a n F lu o re s c e n c e IM301 IM302Benchmark 171 M e a n F lu o re s c e n c e IM302 -10 -9 -8 -7 -6 0 5 , 0 1 , 0 15 , 0 Log [MAb], M M e a n F lu o re s c e n c e Benchmark -10 -9 -8 -7 -6 0 50,000 100,000 150,000 hCLDN6 hCLDN9 hCLDN3 hCLDN4 Log [MAb], M M e a n F lu o re s c e n c e IM301 2Benchmark Key Takeaways • Benchmark (IMAB027) exhibits off target binding to CLDN9 • 1st generation Context mAb (IM301, IM302) exhibit high CLDN6 selectivity • 2nd generation Context mAb (data not shown) exhibit even greater CLDN6 selectivity than IM301 and IM302
CLDN6xCD3 Bispecific Antibody Library CLDN6 x CD3 Bispecific Program Bispecific antibodies retain high CLDN6 specificity Clinical Benchmark Bispecific Formats Log [Bispecific] (M) CLDN9 Reactivity % C y to to x ic it y -4 -3 -2 -1 0 1 2 0 50 100 Candidate Panel 1 - OV90 IMC-16-10 IMC-16-3 IMC-16-15 IMC-16-13 IMC-2-13 IMC-2-7 IMC-20-21 IMC-20-4 IMC-20-15 IMC-20-13 IMC-21-1 IMC-21-6 IMC-2-C3 (BioNtech) IMC-2-C3 (BioNtech) -4 -3 -2 -1 0 1 2 0 50 100 Candidate Panel 1 - OV90 IMC-16-10 IMC-16-3 IMC-16-15 IMC-16-13 IMC-2-13 IMC-2-7 I 20 21 IMC-20-4 20 15 20 3 I 21 I - 1-6 I - -C3 (BioNtech) I - -C3 (BioNtech) -4 -3 -2 -1 0 1 2 0 50 100 Candidate Panel 1 - OV90 16 10 I - -3 16-15 16-13 I -1 -7 0-21 4 0 5 0 13 1 1 1 6 -C3 (BioNtech) -C3 (BioNtech) -4 -3 -2 -1 0 1 2 0 50 100 Candidate Panel 1 - OV90 0 5 3 13 -7 21 4 5 13 1 6 i t -C3 (BioNtech) -4 -3 -2 -1 0 1 2 0 50 100 Candidate Panel 1 - OV90 IMC-16-10 IMC-16-3 IMC-16-15 IMC-16-13 IMC-2-13 IMC-2-7 IMC-20-21 IMC-20-4 IMC-20-15 IMC-20-13 IMC-21-1 IMC-21-6 IMC-2-C3 (BioNtech) IMC-2-C3 (BioNtech) Clinical Benchmark Bispecific Formats -3 -2 -1 0 1 2 0 50 100 Log [Bispecific] (nM) Candidate Panel 1 - OV90 IMC-16-10 IMC-16-3 IMC-16-15 IMC-16-13 IMC-2-13 IMC-2-7 IMC-20-21 IMC-20-4 IMC-20-15 IMC-20-13 IMC-21-1 IMC-21-6 IMC-2-C3 (BioNtech) IMC-2-C3 (BioNtech) T-cell Dependent CytotoxicityCLDN9 R activity Bispecifics induce robust T-cell dependent cytotoxicity Rucker et al., Development of CLDN6 bispecific antibodies for treatment of ovarian cancer, AACR 2022 Bi pecific Formats Ben hmark (IMAB027) Context Therapeutics Inc. - August 202221
Corporate 22 Context Therapeutics Inc. - August 2022
Context Therapeutics Inc. - August 202223 Corporate Experienced Team • Experienced team with deep oncology experience • Our CMO led the clinical development of multiple blockbuster drugs for female cancers, including Kisqali, Arimidex, and Afinitor • Our management team is supported by a Board with strong public company operating and governance experience Focus on Execution Martin Lehr CEO and Director Tarek Sahmoud, MD, PhD Chief Medical Officer Evan Dick, PhD SVP R&D Alex Levit, Esq Chief Legal Officer Jennifer Minai, CPA Chief Financial Officer Chris Beck, MBA SVP Operations Priya Marreddy, MS VP Clinical Operations Mark Fletcher, PhD VP R&D
Recent and Upcoming Milestones ONA-XR Q4 2021 1H 2022 2H 2022 2023 Breast – Window of Opportunity data presentation Breast – AACR preclinical update Breast – Oral SERD clinical trial collaboration Endometrial – Phase 2 trial update Granulosa Cell – Combination Phase 2 trial update Breast – 2L/3L (post-CDK4/6) Phase 2 trial update Breast – 1L (ctDNA enriched) Phase 1b trial update Context Therapeutics Inc. - August 202224 Corporate Claudin 6 Q4 2021 1H 2022 2H 2022 2023 AACR preclinical update Development candidate Selection
Corporate Investment Highlights Female Cancers Large Unmet Need Progesterone Receptor and Claudin 6 High Value Targets Multiple Data Readouts in 2022 Near-Term Milestones Deep Domain Experience, Track Record of Success Strong Team Expected Cash Runway into Q4 2023 Financial Strength Context Therapeutics Inc. - August 202225
BRINGING CHANGE FOR FEMALE CANCERS © CONTEXT THERAPEUTICS 2022